753675
Last Update Posted: 2016-10-10
Recruiting has ended
All Genders accepted | 18 Years + |
174 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer
The primary objective of the trial is to determine the efficacy of VANDETANIB monotherapy or VANDETANIB plus GEMCITABINE or PLACEBO plus GEMCITABINE in prolonging the progression-free survival (PFS) at the trial closure in patients with advanced (unresectable or metastatic) biliary tract cancer.
Eligibility
Relevant conditions:
Biliary Tract Cancer
Gallbladder Cancer
Cancer Of The Extrahepatic Bile Duct
Ampullary Carcinoma
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov